+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma

Ceramide-Fabricated Co-Loaded Liposomes for the Synergistic Treatment of Hepatocellular Carcinoma

Aaps Pharmscitech 19(5): 2133-2143

Combination therapy is one of the important methods to improve therapeutic effect on the treatment of hepatocellular carcinoma (HCC). Sorafenib (SF) is a canonical US Food and Drug Administration-approved multikinase molecule inhibitor against HCC. However, therapeutic benefit with Sorafenib alone was usually unsatisfactory. Ceramide (CE) is an endogenous bioactive sphingolipid, which has a strong potential to suppress various tumors. The combination of SF and CE was hoping to exert maximum synergistic antitumor effect through different tumor-suppressible mechanisms. In this respect, SF and CE co-loaded liposomes (SF/CE-liposomes) were developed to verify synergistic antitumor efficacy. The optimal molar ratio of SF and CE was determined through combination index. SF/CE-liposomes were prepared by thin-film hydration method, which exhibited spherical or ellipsoidal shape. Particle size of SF/CE-liposomes was 174 ± 4 nm with homogeneous distribution. Release profile of SF demonstrated that addition of CE imposed no significant impact on the release of SF. SF/CE-liposomes exhibited acceptable stability in different media and desirable storage stability over 30 days at 4°C. In vitro cellular uptake confirmed that SF/CE-liposomes could be efficiently internalized into HepG2 cells. In vitro cytotoxicity evaluation indicated that SF/CE-liposomes exhibited higher cytotoxicity on HepG2 cells. IC50 value of SF/CE-liposomes was 11.5 ± 0.44 μM, which was significantly lower than that of SF-liposomes (**p < 0.01). Evaluation of in vivo synergistic effect on H22-bearing mice verified that SF/CE-liposomes achieved robust antitumor activity in preventing tumor growth. All results suggested that SF/CE-liposomes might be served as an efficient co-delivery system for improving therapeutic efficacy of HCC.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053768055

Download citation: RISBibTeXText

PMID: 29714002

DOI: 10.1208/s12249-018-1005-4

Related references

Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. International Journal of Pharmaceutics 545(1-2): 261-273, 2018

Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma. Artificial Cells Nanomedicine and Biotechnology 47(1): 1374-1383, 2019

Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. International Journal of Nanomedicine 10: 5123-5137, 2015

Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo. International Journal of Nanomedicine 11: 1395-1412, 2016

Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma. Molecular Pharmaceutics 8(2): 330-337, 2011

Preparation of quercetin and rutin-loaded ceramide liposomes and drug-releasing effect in liposome-in-hydrogel complex system. Biochemical and Biophysical Research Communications 435(3): 361-366, 2013

Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clinical Gastroenterology and Hepatology 11(12): 1636-45.E1-3, 2013

Study on anti-hepatocellular carcinoma of tumor-specific cytotoxicity T lymphocytes from peripheral blood and tumor-infiltrating lymphocytes cytotoxicity in patients with hepatocellular carcinoma activated by dendritic cells loaded with hepatocellular carcinoma antigens. Zhongguo Zhongliu Linchuang 31(11): 604-606, 2004

Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells. Molecular Pharmaceutics 13(2): 428-437, 2016

Combination of doxorubicin with harmine-loaded liposomes exerting synergistic antitumor efficacy. Drug Development and Industrial Pharmacy 44(4): 570-581, 2018

Evaluation of rMETase-Loaded Stealth PLGA/Liposomes Modified with Anti-CAGE scFV for Treatment of Gastric Carcinoma. Journal of Biomedical Nanotechnology 11(7): 1153-1161, 2015

No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer ChemoTherapy and Pharmacology 35(4): 334-338, 1995

Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma. Nanotechnology 30(17): 175101, 2019

Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes. Surgical Oncology Clinics of North America 22(3): 545-561, 2013

Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma. Journal of Pharmaceutical Sciences 99(12): 4874-4879, 2010